All News
RNL 2022: Rheumatoid Arthritis - Best Management
This week's Tuesday Night Rheumatology, hosted by Dr. Jack Cush, featured highlights from the 2022 RheumNow Live Rheumatoid Arthritis - Best Management Pod, followed by a lively audience Q & A. Lectures featured:
Read Article
Recommendations – Good & Bad (5.27.2022)
Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?
Read Article
Cardiovascular Risk in Calcium Pyrophosphate Deposition Disease
The cardiovascular (CV) risks of inflammation and gout are well known, but until recently hasn't been tied to calcium pyrophosphate deposition (CPPD) disease. A recent EHR study shows that acute CPPD crystal arthritis was significantly associated with elevated risks for non-fatal CV events.
Read Article
Can SGLT2 Inhibitors Be Protective in Lupus and Vasculitis?
SGLT2 inhibitors are all the buzz in the renal world with reports of a renal protective and mortality lowering effects
https://t.co/b7YupKPJr7
#MedEd https://t.co/AYPeX360Gv
Links:
Dr. John Cush RheumNow ( View Tweet)
Amitriptyline and FDA Treatments for Fibromyalgia #MedEd
https://t.co/zA4rycnHg4 https://t.co/TxD1jp6XGf
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Lupus Nephritis: The Blind Men and the Kidney with Dr. Joan Merrill
Joan Merrill discusses treatment of lupus nephritis. This was previously recorded at RheumNow Live 2022.
https://t.co/9GRw5VGTKr https://t.co/PS6aEk1fsx
Links:
Dr. John Cush RheumNow ( View Tweet)
Visit @RheumNow podcast channel & hear experts from the #SLEEducatorsNetwork review a new framework for defining disease modification in SLE and why there’s a need to consider therapies that modify the immunologic mechanisms of SLE. Sponsored by GSK USMA
https://t.co/gsrYmu5ufO https://t.co/Fmt21u3wUN
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on https://t.co/V10S4oVFsv. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?
https://t.co/iaMQZtzdLm https://t.co/Zu9VwKoCAc
Dr. John Cush RheumNow ( View Tweet)
Looking forward to reading/watching the coverage of #EULAR2022 by our outstanding faculty, including Drs., Rachel Tate @uptoTate, Kathryn Dao @KDAO2011,
Robert Chao @doctorRBC , Janet Pope @Janetbirdope and Antoni Chan @synovialjoints . https://t.co/oBQCxzdzfF
Dr. John Cush RheumNow ( View Tweet)
Join experts from the #SLEEducatorsNetwork to learn more about our current understanding of SLE pathophysiology & why, given its progressive nature, there’s a need to try to change the course of this complex disease. Sponsored by GSK USMA @jeevsmd https://t.co/WkL1lU2JRJ https://t.co/g8iv6WUG5k
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Novel Treatment of SLE
Dr. Sonali Narain discusses new insights on existing treatments and newly approved therapy and soon to be approved therapies for SLE. #MedEd
https://t.co/7Op3R8IzV1
#MedEdTwitter https://t.co/qBMTbOBmyM
Links:
Dr. John Cush RheumNow ( View Tweet)
Long COVID Manifestations
The acute consequences of a SARS-CoV-2 infection may be bothersome or devastating, but the long-term consequences may lead to so-called "long COVID" syndrome. Long COVID appears to affect up to 20% of those who survive COVID-19.
https://t.co/BFgazzEQWl https://t.co/0HyWZ3HcLG
Links:
Dr. John Cush RheumNow ( View Tweet)
Novel patient self-drawn capillary (CAP) tube blood testing for CRP/RF/CCP - YES, Pt does this at home! 49/50 seropos.RA pts successfully collected samples; , correlations w/ venous blood=excellent: CRP (0.992), CCP (0.984), RF (0.994) https://t.co/zLiwEpiyi9
Conclusions
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Treatment Choices in Refractory RA
Dr. Cush presents Treatment Choices in Refractory RA, during the RheumNow Live 2022 meeting held in March 2022. #MedEd
https://t.co/5wjLyVAS7o https://t.co/dnh8Y5Of4G
Links:
Dr. John Cush RheumNow ( View Tweet)
UK experience with 7 cases of monkeypox. Common sxs=fever, rash, HA, lymphadenopathy, LFTs. Complications =pneumonitis, encephalitis, keratitis, bacterial infx. Often skin lesions, abscesses https://t.co/OW3VMtGTGD https://t.co/yTKODreXYg
Links:
Dr. John Cush RheumNow ( View Tweet)
To TDM or Not in Rheumatology?
Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. But now, EULAR has a recommendation...
https://t.co/u86Vd8bFGr
#MedEdTwitter https://t.co/IpKqPoWM9R
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Adherence to Rheumatoid Therapies
Dr. Michaud presents Adherence to Rheumatoid Therapies at the RheumNow Live 2022 meeting held in March. #MedEd
https://t.co/sCCnx82ptN https://t.co/GJE0Ktwm7B
Links:
Dr. John Cush RheumNow ( View Tweet)
Visit @RheumNow podcast channel & hear experts from the #SLEEducatorsNetwork review a new framework for defining disease modification in SLE and why there’s a need to consider therapies that modify the immunologic mechanisms of SLE. Sponsored by GSK USMA https://t.co/6HiO63Rthd https://t.co/7rjgj1WqGj
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Juvenile Spondyloarthritis
Dr. Pamela Weiss demystifies juvenial SpA and discusses the unique aspects of the disease.
https://t.co/xa2mO0fdzq
#MedEd https://t.co/6JVUGRx5Go
Links:
Dr. John Cush RheumNow ( View Tweet)
1049 non-diabetic hospitalized gout pts (2014 -2020); saw an inverse relationship betw CKD & NAFLD, & increaseing negative associations w/ NAFLD severity (mild OR 0.392; Mod: 0.379; Severe 0.148). NAFLD negatively assoc w/ CKD risk in gout https://t.co/5fuIiO1LwM https://t.co/Jp8CjWkn5m
Links:
Dr. John Cush RheumNow ( View Tweet)